 | • レポートコード：B-MOR-040821 • 出版社/出版日：Mordor Intelligence / 2018年2月 • レポート形態：英文、PDF、114ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：医療・バイオ |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、核医学の世界市場について調べ、核医学の世界規模、市場動向、市場環境、診断別（SPECT（シンチカメラ）、PET（陽電子放出断層撮影））分析、治療別（アルファ放射体、ベータ放射体、近接照射療法）分析、用途別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・核医学の世界市場インサイト ・核医学の世界市場環境 ・核医学の世界市場動向 ・核医学の世界市場規模 ・核医学の世界市場規模：診断別（SPECT（シンチカメラ）、PET（陽電子放出断層撮影）） ・核医学の世界市場規模：治療別（アルファ放射体、ベータ放射体、近接照射療法） ・核医学の世界市場規模：用途別 ・核医学の世界市場：地域別市場規模・分析 ・核医学の北米市場規模・予測 ・核医学のアメリカ市場規模・予測 ・核医学のヨーロッパ市場規模・予測 ・核医学のアジア市場規模・予測 ・核医学の日本市場規模・予測 ・核医学の中国市場規模・予測 ・核医学のインド市場規模・予測 ・核医学の韓国市場規模・予測 ・関連企業情報・競争状況 |
Nuclear medicine falls under the field of molecular imaging, which involves the usage of very small amount of radioactive material (radiopharmaceuticals) to diagnose and treat disease. In nuclear medicine imaging, the radioisotopes are detected by the special type of cameras attached to the computer, which, in turn, provide very precise pictures of the area of the body examined. The global nuclear medicine market is expected to register a CAGR of 12% during the forecast period, 2018 to 2023.
Increasing Incidence of Cancer and Cardiac Ailments
Increasing incidence of cancer and cardiac ailments are the major drivers for the market. Nuclear medicine shows a huge potential in treating cardiac and cancer diseases. According to a survey by National Cancer Institute, the number of new cases of cancer sites was 460 per 100,000 men and woman per year, while the number of deaths was 176 per 100,000 men and women per year. Cardiology applications will continue to demonstrate strong growth in the market.
Other factors, such as increasing SPECT and PET applications and growing public awareness for healthcare are going to drive the market in the future.
Strict Regulatory guidelines
Regulatory requirements pose another hurdle to translational research and clinical investigations. In the United States, all pharmacologic agents, including diagnostic radiopharmaceuticals and radio therapeutics, undergo regulatory oversight by FDA. Radiopharmaceuticals face additional scrutiny and undergo unique regulatory and approval pathways. Sometimes, extensive toxicology testing poses considerable financial burdens for the investigators.
Additionally, reimbursement hurdles for the manufacturer and high capital investment are also restraining the market growth.
North America to Dominate the Market
The nuclear medicine market is segmented by diagnostics, therapeutics, application, and by geography. By geography, it is segmented into North America, Europe, Asia-Pacific, the Middle East & Africa, and South America.
North America is the dominant market for diagnostic radioisotopes. Within North America, the United States is the largest consumer market for radioisotopes, and Canada is the largest producer of Tc-99m.
Key Developments in the Market
• April, 2017: IBA Molecular and Mallinckrodt Nuclear Medicine LLC united to create Curium – a world-class provider in nuclear imaging.
• October, 2017: Switzerland’s Novartis agreed to pay USD 3.9 billion to take over French nuclear medicines business of Advanced Accelerator Applications, aimed to strengthen its cancer treatment activities.
Major Players: CURIUM, LANTHEUS MEDICAL IMGAGING, TRIAD ISOTOPES, SIEMENS HEALTHINEER, BRACCO, CAMBRIDGE ISOTOPE LABORATORIES INC., CARDINAL HEALTH INC., GE HEALTHCARE, NORDION INC., FUJIFILM HOLDINGS CORPORATION, ECZACIBASI-MONROL amongst others.
Reasons to Purchase this Report
• Market analysis for the global nuclear medicine market, with region-specific assessments and competition analysis on a global and regional scale.
• Analyzing various perspectives of the industry with the help of Porter’s five forces analysis
• The treatment type that is expected to dominate the market
• Regions that are expected to witness fastest growth during the forecast period
• Identify the latest developments, market shares and strategies employed by the major market players.
• 3 months analyst support, along with the Market Estimate sheet in excel.
Customization of the report
• This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.
レポート目次1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Market Overview
5.3 Porter’s Five Force Analysis
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Degree of Competition
5.3.4 Threat of Substitution
5.3.5 Threat of New Entrants
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increasing Incidents of Cancer and Cardiac Ailments
6.1.2 Increasing SPECT and Pet Applications
6.1.3 Growing Public Awareness for Healthcare
6.2 Market Restraints
6.2.1 Short Half Life of Radiopharmaceuticals
6.2.2 High Capital Investment
6.2.3 Strict Regulatory Guidelines
6.3 Opportunities
6.3.1 Increasing Imaging Technologies
6.3.2 Potential Radioisotopes in Pipeline
6.3.3 Increasing Neurological Applications
6.3.4 Cyclotron Based Production
6.4 Challenges
6.4.1 Shutdown of Nuclear Reactors
7. Market Segmentation
7.1 By Diagnostics
7.1.1 SPECT Market
7.1.2 PET
7.2 By Therapeutics
7.2.1 Alpha Emitters
7.2.2 Beta Emitters
7.2.3 Brachytherapy
7.3 By Application
7.3.1 Diagnostics
7.3.2 Therapeutics
7.4 By Geography
7.4.1 North America
7.4.1.1 US
7.4.1.2 Canada
7.4.1.3 Mexico
7.4.2 Europe
7.4.2.1 Germany
7.4.2.2 UK
7.4.2.3 France
7.4.2.4 Italy
7.4.2.5 Spain
7.4.2.6 Rest of Europe (RoE)
7.4.3 Asia Pacific
7.4.3.1 Japan
7.4.3.2 China
7.4.3.3 India
7.4.3.4 South Korea
7.4.3.5 Australia
7.4.3.6 Rest of Asia Pacific
7.4.4 The Middle East & Africa
7.4.4.1 GCC Countries
7.4.4.2 South Africa
7.4.4.3 Rest of Middle East & Africa
7.4.5 South America
7.4.5.1 Brazil
7.4.5.2 Argentina
7.4.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisitions
8.2 Agreements, Collaborations & Partnerships
8.3 New Product Launches
9. Key Players
9.1 Curium
9.2 Lantheus Medical Imaging
9.3 Triad Isotopes
9.4 Siemens Healthineers
9.5 Bracco
9.6 Cambridge Isotope Laboratories Inc.
9.7 Cardinal Health Inc.
9.8 GE Healthcare
9.9 Nordion, Inc.
9.10 Fujifilm Holdings Corporation
9.11 Eczacibasi-Monrol
10. Future of the Market